Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
MicroPort CardioFlow Medtech Corp. ( (HK:2160) ) just unveiled an announcement.
MicroPort CardioFlow Medtech announced that its independently developed ENO Series pacemakers have received CE approval for left bundle branch area pacing, meaning all six of its CE‑certified pacemakers are now cleared for this advanced indication. Combined with its FLEXIGO 3D LBBAP delivery system and Vega M58 leads, the company now offers a complete LBBAP therapy solution aimed at improving cardiac function and expanding its addressable patient base.
LBBAP is an emerging international physiological pacing technique that more closely mimics the heart’s natural conduction system, potentially reducing heart failure risk associated with traditional pacing methods. By securing broad CE indications and highlighting features such as MRI compatibility, Bluetooth connectivity, remote monitoring, and intelligent MRI adaptation, MicroPort CardioFlow strengthens its competitive positioning in high‑end cardiac pacing and opens additional revenue and clinical adoption opportunities as LBBAP gains guideline support worldwide.
More about MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corporation is a Hong Kong‑listed medical technology company specializing in cardiac rhythm management and physiological pacing solutions. Its portfolio includes CE‑certified pacemakers, LBBAP delivery systems and leads, targeting patients with bradycardia and conduction disorders in international cardiovascular implant markets.
Average Trading Volume: 1,513,497
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.02B
See more insights into 2160 stock on TipRanks’ Stock Analysis page.